中国免疫学杂志
中國免疫學雜誌
중국면역학잡지
Chinese Journal of Immunology
2015年
10期
1304-1309,1314
,共7页
王亚群%韩秋菊%庞敏%张建
王亞群%韓鞦菊%龐敏%張建
왕아군%한추국%방민%장건
STAT3%Decoy%阿霉素%肝癌
STAT3%Decoy%阿黴素%肝癌
STAT3%Decoy%아매소%간암
STAT3%Decoy%Doxorubicin%HCC
目的：探讨STAT3阻断剂Decoy ODN 与临床常用肝癌化疗药阿霉素（Doxorubicin）、5－氟尿嘧啶（5－Fu）和顺铂（cisplatin）联合使用对肝癌的治疗效果及其对免疫系统的影响。方法：肝癌细胞转染Decoy ODN 后用化疗药处理，以MTT法检测肝癌细胞的增殖能力，Annexin－V／7AAD 双染法检测细胞凋亡率；对H22荷瘤小鼠进行Decoy ODN 和阿霉素联合治疗，观察小鼠肿瘤生长情况以及生存期；流式细胞术检测治疗后小鼠PBMC 的细胞分群和活化水平，以及阿霉素或阿霉素处理的肿瘤细胞对小鼠脾脏淋巴细胞体外活化作用。结果：转染Decoy ODN 以后，阿霉素对H22细胞的抑制作用显著增强，H22细胞凋亡率也明显升高。Decoy ODN 和阿霉素联合治疗可明显降低小鼠肿瘤生长速度并延长荷瘤小鼠的生存期；低剂量阿霉素增加了PBMC 中T 细胞的比例和CD69分子的表达，以及NK 细胞CD107a 和IFN－γ的表达；阿霉素处理的H22细胞可促进T细胞比例的升高。结论：Decoy ODN 阻断肝癌细胞STAT3后可以增强肝癌细胞H22对阿霉素的敏感性，提高化疗效果，降低化疗毒副作用，改善机体免疫功能。
目的：探討STAT3阻斷劑Decoy ODN 與臨床常用肝癌化療藥阿黴素（Doxorubicin）、5－氟尿嘧啶（5－Fu）和順鉑（cisplatin）聯閤使用對肝癌的治療效果及其對免疫繫統的影響。方法：肝癌細胞轉染Decoy ODN 後用化療藥處理，以MTT法檢測肝癌細胞的增殖能力，Annexin－V／7AAD 雙染法檢測細胞凋亡率；對H22荷瘤小鼠進行Decoy ODN 和阿黴素聯閤治療，觀察小鼠腫瘤生長情況以及生存期；流式細胞術檢測治療後小鼠PBMC 的細胞分群和活化水平，以及阿黴素或阿黴素處理的腫瘤細胞對小鼠脾髒淋巴細胞體外活化作用。結果：轉染Decoy ODN 以後，阿黴素對H22細胞的抑製作用顯著增彊，H22細胞凋亡率也明顯升高。Decoy ODN 和阿黴素聯閤治療可明顯降低小鼠腫瘤生長速度併延長荷瘤小鼠的生存期；低劑量阿黴素增加瞭PBMC 中T 細胞的比例和CD69分子的錶達，以及NK 細胞CD107a 和IFN－γ的錶達；阿黴素處理的H22細胞可促進T細胞比例的升高。結論：Decoy ODN 阻斷肝癌細胞STAT3後可以增彊肝癌細胞H22對阿黴素的敏感性，提高化療效果，降低化療毒副作用，改善機體免疫功能。
목적：탐토STAT3조단제Decoy ODN 여림상상용간암화료약아매소（Doxorubicin）、5－불뇨밀정（5－Fu）화순박（cisplatin）연합사용대간암적치료효과급기대면역계통적영향。방법：간암세포전염Decoy ODN 후용화료약처리，이MTT법검측간암세포적증식능력，Annexin－V／7AAD 쌍염법검측세포조망솔；대H22하류소서진행Decoy ODN 화아매소연합치료，관찰소서종류생장정황이급생존기；류식세포술검측치료후소서PBMC 적세포분군화활화수평，이급아매소혹아매소처리적종류세포대소서비장림파세포체외활화작용。결과：전염Decoy ODN 이후，아매소대H22세포적억제작용현저증강，H22세포조망솔야명현승고。Decoy ODN 화아매소연합치료가명현강저소서종류생장속도병연장하류소서적생존기；저제량아매소증가료PBMC 중T 세포적비례화CD69분자적표체，이급NK 세포CD107a 화IFN－γ적표체；아매소처리적H22세포가촉진T세포비례적승고。결론：Decoy ODN 조단간암세포STAT3후가이증강간암세포H22대아매소적민감성，제고화료효과，강저화료독부작용，개선궤체면역공능。
Objective:To investigate the theraputic effect of STAT3 Decoy-ODN combined with chemotherapy drugs for HCC commonly used in clinical,include doxorubicin (DOX),5-fluorouracil (5-Fu) and cisplatin;and,analyzing the impact of combination therapy on the immune system.Methods:MTT assay was used to detect cell proliferation,and Annexin-V /7AAD double staining assay was used to detect the apoptosis of Decoy ODN transfected-hepatoma cells treated with chemotherapy drugs.The tumor growth and survival rate of H22 tumor-bearing mice treated with DOX combined with STAT3 Decoy-ODN or not were observed.FACS was applied to analyze the subpopulation and activation of PBMCs from tumor-bearing mice treated as above,and to evaluate the influence of DOX or DOX-treated tumor cells on spleen lymphocyte activation.Results: DOX-induced the suppression and the apoptosis of H22 were significantly increased by Decoy ODN transfection.The combination treatment of Decoy ODN and DOX significantly reduced H22 tumor growth and extended the survival of tumor-bearing mice.Low-dose DOX could increase the proportion of T cells and CD69+T cells in PBMCs,as well as the expression of CD107a and IFN-γin NK cells.DOXt-reated H 22 cells increased the proportion of T cells.Conclusion:Targeted blocking STAT3 could enhance the sensitivity of liver cancer cells to doxorubicin.So,combination therapy may improve DOX therapeutic effect and reduce DOX-mediated side effects.Furthermore,low dose of DOX can promote the activation of host immune system by acting on tumor cells.
